within Pharmacolibrary.Drugs.ATC.M;

model M05BX04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 1.3333333333333334e-07,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0018,
    k12             = 0.013,
    k21             = 0.013
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M05BX04</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Denosumab is a fully human monoclonal antibody that inhibits RANK ligand (RANKL), a key mediator of osteoclast formation, function, and survival, thus reducing bone resorption and increasing bone mass. It is approved for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, as well as for bone loss associated with certain cancers and for prevention of skeletal-related events in patients with bone metastases.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adults (including postmenopausal women with osteoporosis) after subcutaneous administration of denosumab 60 mg.</p><h4>References</h4><ol><li><p>Sohn, W, et al., &amp; Jang, G (2014). The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. <i>British journal of clinical pharmacology</i> 78(3) 477–487. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12355&quot;>10.1111/bcp.12355</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24548274/&quot;>https://pubmed.ncbi.nlm.nih.gov/24548274</a></p></li><li><p>Zhang, S, et al., &amp; Jiang, Z (2024). Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence Trial. <i>JAMA oncology</i> 10(4) 448–455. DOI:<a href=&quot;https://doi.org/10.1001/jamaoncol.2023.6520&quot;>10.1001/jamaoncol.2023.6520</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38329745/&quot;>https://pubmed.ncbi.nlm.nih.gov/38329745</a></p></li><li><p>Wang, S, et al., &amp; Xiang, Y (2022). Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects. <i>Expert opinion on investigational drugs</i> 31(10) 1133–1142. DOI:<a href=&quot;https://doi.org/10.1080/13543784.2022.2120389&quot;>10.1080/13543784.2022.2120389</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36045484/&quot;>https://pubmed.ncbi.nlm.nih.gov/36045484</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M05BX04;
